Is Anbio Biotechnology halal to invest in?

According to Musaffa's Shariah screening methodology, Anbio Biotechnology (NNNN) is currently classified as HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Anbio Biotechnology a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Anbio Biotechnology using these criteria to determine its compliance status.

Can Muslims buy shares of Anbio Biotechnology?

Muslim investors may consider investing in Anbio Biotechnology if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Anbio Biotechnology classified as HALAL?

Musaffa determines the Shariah status of Anbio Biotechnology by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Anbio Biotechnology updated?

The Shariah compliance status of Anbio Biotechnology may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Anbio Biotechnology become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Anbio Biotechnology?

You can check the latest Shariah compliance status of Anbio Biotechnology on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

NNNN Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: April 29, 2026

Report Source: 2025 Annual Report

Anbio Biotechnology. Stock Analysis NNNN

United States Health Care Mid Cap Report: 2025 Annual

Anbio Biotechnology is a medical device company. The company is headquartered in Frankfurt, Hessen and currently employs 27 full-time employees. The company went IPO on 2025-02-19. The firm is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).

Key Statistics of Anbio Biotechnology (NNNN)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$25.15$27.88

Today's Open

$25.49

Volume

19.83K

P/E Ratio (TTM)

605.36

52 Week Range

$6.80$55.65

Market Cap

4.20B

Avg. Volume

25.01K

Dividend Yield

Financial Metrics & Statements of Anbio Biotechnology (NNNN)

FAQ's for Anbio Biotechnology (NNNN)

According to Musaffa’s Shariah screening methodology, Anbio Biotechnology (NNNN) is currently classified as HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.